Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Second- or Later-Line Therapy in Chinese Patients With HER2 Positive Advanced Breast Cancer

NCT05945927 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05945927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05945927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Second- or Later-Line Therapy in Chinese Patients With HER2 Positive Advanced Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
September 13, 2023
Completion date
August 30, 2025
Enrollment
178 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer